FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169455665> ?p ?o ?g. }

• W2169455665 endingPage "77" @default.
• W2169455665 startingPage "869" @default.
• W2169455665 abstract "Urokinase-type plasminogen activator (uPA), its receptor (uPAR) and its inhibitor PAI-1, play a key role in tumor invasion and metastasis. uPA and PAI-1 were the first novel tumor biological factors to be validated at the highest level of evidence regarding their clinical utility in breast cancer. Their antigens are determined in tumor tissue extracts by standardized, quality-assured immunometric assays (ELISA). Since the late 1980s, numerous independent studies have demonstrated that patients with low levels of uPA- and PAI-1 in their primary tumor tissue have significantly better survival than patients with high levels of either factor. However, it is unclear whether it is their (relative) levels in the tumor stroma or in the tumor cells themselves that is most relevant to patient outcome. This missing knowledge leads to an uncertainty concerning the management of breast cancer tissue specimens. It is unclear how much tumor stroma is allowed in one tumor tissue specimen for an adequate assessment of the patients' outcome. This is the first study in which tumor cells and stromal tissue of invasive breast carcinomas (n=60) were separated by laser capture microdissection followed by ELISA-based determination of the uPA-, uPAR- and PAI-1-levels. In addition, we have assessed uPA-, uPAR- and PAI-1 distribution in formalin-fixed, paraffin-embedded breast cancer specimens (n=60) by immunohistochemistry. The uPA-, uPAR- and PAI-1 in tumor stroma only, tumor cells only and not separated tumor tissue did not show any significant differences in protein-levels determined by ELISA. Cox regression analysis showed that patients with high uPA-, high uPAR-, and/or high PAI-1-levels, as compared to patients with low levels of either factor, showed a significantly shorter relapse-free survival and overall survival (p=0.000001). These results suggest that a strong expression of uPA, uPAR and PAI-1 in the tumor stroma, as well as in tumor cells, have the same impact on the clinical behaviour of breast cancer.When using uPA- and PAI-1 levels as prognostic and predictive factors in breast cancer the quantity of tumor stroma in the tumor tissue specimen is not relevant for the assessment of the patients' outcome." @default.
• W2169455665 created "2016-06-24" @default.
• W2169455665 creator A5025744948 @default.
• W2169455665 creator A5034981822 @default.
• W2169455665 creator A5041365856 @default.
• W2169455665 creator A5062202081 @default.
• W2169455665 creator A5062587352 @default.
• W2169455665 creator A5078745756 @default.
• W2169455665 creator A5088247085 @default.
• W2169455665 date "2009-07-01" @default.
• W2169455665 modified "2023-09-25" @default.
• W2169455665 title "Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact." @default.
• W2169455665 cites W10822187 @default.
• W2169455665 cites W1556470644 @default.
• W2169455665 cites W1559797510 @default.
• W2169455665 cites W1724539534 @default.
• W2169455665 cites W1973343326 @default.
• W2169455665 cites W1976221474 @default.
• W2169455665 cites W1979300931 @default.
• W2169455665 cites W1999708653 @default.
• W2169455665 cites W2010871781 @default.
• W2169455665 cites W2034680111 @default.
• W2169455665 cites W2049236625 @default.
• W2169455665 cites W2051300009 @default.
• W2169455665 cites W2065981710 @default.
• W2169455665 cites W2076313402 @default.
• W2169455665 cites W2085430724 @default.
• W2169455665 cites W2085628794 @default.
• W2169455665 cites W2105488671 @default.
• W2169455665 cites W2145332495 @default.
• W2169455665 cites W2148291626 @default.
• W2169455665 cites W2187334005 @default.
• W2169455665 cites W2314203153 @default.
• W2169455665 cites W2340386540 @default.
• W2169455665 cites W2405155277 @default.
• W2169455665 cites W2405442768 @default.
• W2169455665 doi "https://doi.org/10.14670/hh-24.869" @default.
• W2169455665 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19475533" @default.
• W2169455665 hasPublicationYear "2009" @default.
• W2169455665 type Work @default.
• W2169455665 sameAs 2169455665 @default.
• W2169455665 citedByCount "16" @default.
• W2169455665 countsByYear W21694556652013 @default.
• W2169455665 countsByYear W21694556652014 @default.
• W2169455665 countsByYear W21694556652015 @default.
• W2169455665 countsByYear W21694556652016 @default.
• W2169455665 countsByYear W21694556652017 @default.
• W2169455665 countsByYear W21694556652019 @default.
• W2169455665 countsByYear W21694556652020 @default.
• W2169455665 countsByYear W21694556652021 @default.
• W2169455665 countsByYear W21694556652022 @default.
• W2169455665 crossrefType "journal-article" @default.
• W2169455665 hasAuthorship W2169455665A5025744948 @default.
• W2169455665 hasAuthorship W2169455665A5034981822 @default.
• W2169455665 hasAuthorship W2169455665A5041365856 @default.
• W2169455665 hasAuthorship W2169455665A5062202081 @default.
• W2169455665 hasAuthorship W2169455665A5062587352 @default.
• W2169455665 hasAuthorship W2169455665A5078745756 @default.
• W2169455665 hasAuthorship W2169455665A5088247085 @default.
• W2169455665 hasConcept C121608353 @default.
• W2169455665 hasConcept C126322002 @default.
• W2169455665 hasConcept C142724271 @default.
• W2169455665 hasConcept C16930146 @default.
• W2169455665 hasConcept C204232928 @default.
• W2169455665 hasConcept C2778001805 @default.
• W2169455665 hasConcept C2779013556 @default.
• W2169455665 hasConcept C2779256057 @default.
• W2169455665 hasConcept C2779679481 @default.
• W2169455665 hasConcept C502942594 @default.
• W2169455665 hasConcept C52124034 @default.
• W2169455665 hasConcept C530470458 @default.
• W2169455665 hasConcept C56219504 @default.
• W2169455665 hasConcept C71924100 @default.
• W2169455665 hasConcept C86803240 @default.
• W2169455665 hasConceptScore W2169455665C121608353 @default.
• W2169455665 hasConceptScore W2169455665C126322002 @default.
• W2169455665 hasConceptScore W2169455665C142724271 @default.
• W2169455665 hasConceptScore W2169455665C16930146 @default.
• W2169455665 hasConceptScore W2169455665C204232928 @default.
• W2169455665 hasConceptScore W2169455665C2778001805 @default.
• W2169455665 hasConceptScore W2169455665C2779013556 @default.
• W2169455665 hasConceptScore W2169455665C2779256057 @default.
• W2169455665 hasConceptScore W2169455665C2779679481 @default.
• W2169455665 hasConceptScore W2169455665C502942594 @default.
• W2169455665 hasConceptScore W2169455665C52124034 @default.
• W2169455665 hasConceptScore W2169455665C530470458 @default.
• W2169455665 hasConceptScore W2169455665C56219504 @default.
• W2169455665 hasConceptScore W2169455665C71924100 @default.
• W2169455665 hasConceptScore W2169455665C86803240 @default.
• W2169455665 hasIssue "7" @default.
• W2169455665 hasLocation W21694556651 @default.
• W2169455665 hasOpenAccess W2169455665 @default.
• W2169455665 hasPrimaryLocation W21694556651 @default.
• W2169455665 hasRelatedWork W1556470644 @default.
• W2169455665 hasRelatedWork W1970018230 @default.
• W2169455665 hasRelatedWork W1978787163 @default.
• W2169455665 hasRelatedWork W1987349436 @default.
• W2169455665 hasRelatedWork W2005113904 @default.

• next